대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Fenofibrate-Associated Nephrotoxicity in Pateints with Chronic Kidney Disease
저자	JEONGGU NA, Tae Won LEE, Eunjin Bae, Junhyeong Cho, Se-Ho Chang, Ha Nee Jang, Hyun Seop Cho, Dong Jun Park
출판정보	2020; 2020(1):
키워드	Fenofibrate \| nephrotoxicity \| CKD
초록	Fenofibrate is widely used to treat hypertriglyceridemia for many years. It is well known that fenofibrate can trigger acute kidney injury. We studied to investigate the relationship between acute kidney injury and fenofibrate. We retrospectively evaluated the medical records of patients to start fenofibrate prescription for hypertriglyceridemia from January 2010 to December 2018 in the tertiary hospital. We reviewed their underlying disease, laboratory findings, dose of fenofibrate, duration of fenofibrate, and concomitant drug use. We did the effort to find factors related to acute kidney injury by fenofibrate. Total 267 patients were included. The mean age was 63.4 years old. 96 of 267 patients had acute kidney injury(36.0%). Patients with diabetes mellitus showed significantly increased risk of acute kidney injury without diabetes mellitus (27.7% vs 8.2%, p=0.009). We found significant correlation between hypertension and acute kidney injury. (27.3% vs 8.6%, p=0.005). Patients with concomitant use of RAS blockers showed significantly increased risk of acute kidney injury compared with non-use of RAS blockers(29.6% vs 6.4%, p=0.000). 72 of 195 patients had underlying chronic kidney disease(n=72, 27.0%). Mean estimated glomerular filtration rate(eGFR) by MDRD was each 46.6 ± 10.9 mL/min/1.73m² in chronic kidney disease group and 91.3 ± 23.7 mL/min/1.73m² in non-chronic kidney disease group. In subgroup analysis, patients with chronic kidney disease didn’t have statistically significant risk of acute kidney injury by fenofibrate (12.0% vs 12.0%, p=0.079). Diabetes mellitus and concomitant use of RAS blocker have a statistically significant association with acute kidney injury by fenofibrate in our study. And patients with chronic kidney disease didn’t have significant difference in risk in acute kidney injury by fenofibrate. We believe additional large-scale randomized controlled studies are needed.
원문(PDF)	PDF 원문보기

목록

위로가기